To the Editor I read with great interest the systematic review by Leberfinger et al1 on breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). The authors analyze 95 patients with BIA-ALCL and suppose it is caused by a complex process involving many factors, including bacterial biofilm growth, textured implant surface, immune response, and genetics of the patient. They also state that none of the reported patients presented with anaplastic lymphoma kinase,1 which is typically found in 60% of patients with systemic ALCL. Leberfinger et al1 raise the possibility that the BIA-ALCL is related to an inflammatory process secondary to a reaction process to the breast implant. They also speculate that the literature establishes that chronic inflammation can lead to a lymphoma.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Fleury EDFC. Additional Risk Factors for Breast Implant–Associated Anaplastic Large Cell Lymphoma. JAMA Surg. 2018;153(8):780–781. doi:10.1001/jamasurg.2018.1119
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: